← 產業報告目錄
Antibody Hit Generation and Screening Market Size, Share & Trends Analysis Distribution By Application (Cancer, Autoimmune Diseases, Infectious Diseases), Technologies (Hit Generation, Phage Display, Yeast Display, Ribosome Display, B-Cell Hybridoma Technology, Computational Tools, Screening), Antibody Type And Segment Forecasts, 2024-2031
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-02-14頁數 168報告編號 INSIGHTACE-91de2ef221
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
The Antibody Hit Generation and Screening Market is positioned for steady expansion, with a projected CAGR of 9.78% from 2024 to 2031.
At its core, Antibody Hit Generation and Screening pertains to a vital step in developing therapeutic antibodies, focusing on identifying and selecting candidates that bind to a target antigen with high affinity and specif. Stakeholders across the healthcare landscape are surgingly turning to these solutions to meet contemporary demands.
Market momentum is fueled by surging requirement advanced solutions, favorable regulatory frameworks, and robust investment in research and development across major economies.
Segmental analysis reveals differentiated growth across product categories, applications, and geographical regions, with certain niches demonstrating above-average expansion potential.
From a regional perspective, mature markets in North America and Europe continue to hold pronounced shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and surging investment in the sector.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Antibody Hit Generation and Screening Market Snapshot
Chapter 4. Global Antibody Hit Generation and Screening Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Application Estimates & Trend Analysis
5.1. by Application & Market Share, 2019 & 2031
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Application:
5.2.1. Cancer
5.2.2. Autoimmune diseases
5.2.3. Infectious diseases
Chapter 6. Market Segmentation 2: by Technologies Estimates & Trend Analysis
6.1. by Technologies & Market Share, 2019 & 2031
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Technologies:
6.2.1. Hit Generation
6.2.2. Phage display
6.2.3. Yeast display
6.2.4. Ribosome display
6.2.5. B-cell hybridoma technology
6.2.6. Computational tools
6.2.7. Screening
Chapter 7. Market Segmentation 3: by Antibody Type Estimates & Trend Analysis
7.1. by Antibody Type & Market Share, 2019 & 2031
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Antibody Type:
7.2.1. Humanized Antibody
7.2.2. Human Antibody
7.2.3. Chimeric Antibody
7.2.4. Murine Antibody
Chapter 8. Antibody Hit Generation and Screening Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
8.1.2. North America Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by Technologies, 2024-2031
8.1.3. North America Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by Antibody Type, 2024-2031
8.1.4. North America Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
8.2. Europe
8.2.1. Europe Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
8.2.2. Europe Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by Technologies, 2024-2031
8.2.3. Europe Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by Antibody Type, 2024-2031
8.2.4. Europe Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
8.3. Asia Pacific
8.3.1. Asia Pacific Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
8.3.2. Asia Pacific Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by Technologies, 2024-2031
8.3.3. Asia-Pacific Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by Antibody Type, 2024-2031
8.3.4. Asia Pacific Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
8.4. Latin America
8.4.1. Latin America Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
8.4.2. Latin America Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by Technologies, 2024-2031
8.4.3. Latin America Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by Antibody Type, 2024-2031
8.4.4. Latin America Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
8.5. Middle East & Africa
8.5.1. Middle East & Africa Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
8.5.2. Middle East & Africa Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by Technologies, 2024-2031
8.5.3. Middle East & Africa Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by Antibody Type, 2024-2031
8.5.4. Middle East & Africa Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. F. Hoffmann-La Roche Ltd.
9.2.2. AbbVie
9.2.3. Pfizer
9.2.4. AstraZeneca
9.2.5. Novartis
9.2.6. Eli Lilly
9.2.7. WuXi AppTec
9.2.8. Charles River Laboratories
9.2.9. Syngenta
9.2.10. BioLegend
9.2.11. Creative Biolabs
9.2.12. Eurofins CDMO
9.2.13. AbCellera
9.2.14. MorphoSys
9.2.15. Evelo Biosciences
9.2.16. Icos Therapeutics
9.2.17. Argenx
9.2.18. Kymab
9.2.19. Alnylam Pharmaceuticals
9.2.20. SAb Biotherapeutics
9.2.21. Other Prominent Players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們